{"id":685708,"date":"2022-09-15T08:35:45","date_gmt":"2022-09-15T12:35:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effect-on-comt-activity-at-the-2022-mds-international-congress\/"},"modified":"2022-09-15T08:35:45","modified_gmt":"2022-09-15T12:35:45","slug":"neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effect-on-comt-activity-at-the-2022-mds-international-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effect-on-comt-activity-at-the-2022-mds-international-congress\/","title":{"rendered":"Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS\u00ae (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Sept. 15, 2022<\/span><\/span> \/PRNewswire\/ —\u00a0Neurocrine Biosciences, Inc.<\/a>\u00a0(Nasdaq: NBIX) today will present data on the effects of ONGENTYS\u00ae<\/sup> (opicapone) capsules<\/a> on soluble-catechol-O-methyltransferase (S-COMT) enzyme inhibition. These data (abstract #1025) are being shared at the MDS International Congress of Parkinson’s Disease and Movement Disorders\u00ae<\/sup>September 15-18<\/span> in Madrid, Spain<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Neurocrine
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“These data demonstrate that COMT inhibition shown by opicapone leads to more consistent daily levodopa exposure, which continues to be a challenge and goal in treating Parkinson’s disease,” said Eiry W. Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. “Adding a once-daily dose of opicapone 50 mg to levodopa\/carbidopa resulted in inhibition of S-COMT activity and reduced fluctuations in L-dopa concentrations regardless of disease state, age, sex, ethnicity, or BMI.”<\/p>\n

The post-hoc analyses were conducted using data from 2 previous open-label Phase 1 studies of ONGENTYS<\/a>, an approved once-daily adjunctive treatment to levodopa\/carbidopa in patients with Parkinson’s disease experiencing OFF time.\u00a0Results of this post-hoc analysis showed that once-daily ONGENTYS 50 mg, when added to levodopa\/carbidopa, decreased mean S-COMT activity by more than 80 percent in both patients with Parkinson’s disease and healthy participants. Mean percentage reduction in S-COMT activity was 79\u201385 percent for all subgroups in both individual and pooled studies, although some subgroups had small participant numbers. ONGENTYS also reduced inter-patient variability in S-COMT activity by 86 percent from baseline.<\/p>\n

Neurocrine Biosciences will also present survey results (abstract #993) on the continuing educational needs of U.S. clinicians managing OFF episodes in Parkinson’s disease, demonstrating the variability in approach to managing OFF episodes and need for relevant Continuing Medical Education <\/span>approaches.<\/p>\n

A full list of abstracts being presented by Neurocrine Biosciences at MDS International Congress of Parkinson’s Disease and Movement Disorders\u00ae<\/sup> is available on the meeting website<\/a>.<\/p>\n

\n About ONGENTYS\u00ae<\/sup>\u00a0(opicapone) Capsules\u00a0<\/b>
\n
ONGENTYS is a once-daily, oral, peripheral, selective, and reversible catechol-O-methyltransferase (COMT) inhibitor approved by the U.S. Food and Drug Administration (FDA) in April 2020<\/span> as an add-on treatment to levodopa\/carbidopa in patients with Parkinson’s disease experiencing “OFF” episodes. ONGENTYS inhibits the COMT enzyme, which breaks down levodopa, making more levodopa available to reach the brain.<\/p>\n

In June 2016<\/span>, BIAL \u2013 Portela & CA, S.A. (BIAL) received approval from the European Commission for ONGENTYS as an adjunct therapy to preparations of levodopa\/DOPA decarboxylase inhibitors in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. BIAL currently markets ONGENTYS in several European countries. Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada<\/span>.<\/p>\n

\n Important Information (U.S.)<\/b>\n <\/p>\n

\n Approved Use <\/b>
\n
ONGENTYS\u00ae<\/sup> (opicapone) capsules is a prescription medicine used with levodopa and carbidopa in people with Parkinson’s disease (PD) who are having “OFF” episodes.<\/p>\n

It is not known if ONGENTYS is safe and effective in children.<\/p>\n

\n Important Safety Information<\/b>\n <\/p>\n

\n Do not take ONGENTYS if you:<\/b>\n <\/p>\n